Recovery Modalities
Three biotech firms eye Nasdaq listings
Three biotech firms—including ADARx Pharma—are preparing Nasdaq listings, with ADARx targeting a $1.74 billion valuation for its hereditary angioedema therapy.
By Samoyed · Sep 22, 2026
Tag: clinicaltrials
Endocrine Balance
UK drug firms pull out of NICE reviews at record
UK drug firms are pulling out of NICE reviews at record levels in 2026, raising questions about industry shifts or systemic issues in the appraisal...
By Samoyed · Sep 19, 2026
Endocrine Balance
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
The FDA has approved the first gene therapy, Fayuvi, for Sanfilippo syndrome type A, offering hope to affected children.
By emily johnson · Sep 18, 2026
Nutrient Synergy
FDA Pilot Aims to Accelerate U.S. Drug Trials
The FDA's new pilot program aims to accelerate U.S. drug trials, reducing time from discovery to first-in-human studies.
By emily johnson · Sep 17, 2026
Somatic Drills
Pharma struggles as AI fraud erodes patient trust in calls
AI fraud is eroding patient trust in pharma calls, with scammers using voice cloning and spoofing to mimic legitimate pharmaceutical outreach.
By Samoyed · Sep 16, 2026
Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
By emily johnson · Sep 15, 2026
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
By emily johnson · Sep 14, 2026
Nutrient Synergy
AbbVie tests new approach for menstrual migraine treatment
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
By Samoyed · Sep 12, 2026
Endocrine Balance
Biotechs lead fight against cancer
Biotechs lead the fight against cancer with next-generation treatments and clinical trials.
By emily johnson · Sep 11, 2026
Microbiome Diversity
Bristol Myers reports progress in multiple myeloma trial
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
By Samoyed · Sep 9, 2026